Benjamin Oliver Murray

Benjamin Oliver Murray

Auto-generated profile, based on publicly available information

Benjamin Oliver Murray

Centre for Kidney and Bladder Health, Division of Medicine, University College London, London, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Microbiology
Verified
Journal Article
Open access
BMBenjamin Oliver Murray
Benjamin Oliver Murray
RDRobin Dawson
Robin Dawson
LALolwah Mohammad Alsharaf
Lolwah Mohammad Alsharaf
JWJody Winter
Jody Winter
Outer-membrane vesicles (OMVs) produced by Helicobacter pylori deliver bacterial components to host cells, provide a mechanism for stabilization of secreted components and may allow the bacteria to exert ‘long-range’ effects in the gastric niche, promoting persistence. In addition to their well-characterized host cell interactions, membrane vesicles improve stress survival in other bacterial species, and are constitutively produced by both pathogenic and non-pathogenic bacteria. We aimed to determine whether OMVs could improve H. pylori survival of a range of stressors. The effects of purified OMVs on the resistance of H. pylori to a range of environmental and antimicrobial stresses were determined using growth curves and survival assays. Addition of purified OMVs to H. pylori cultures provided dose-dependent protection against hydrogen peroxide-mediated killing. Supplementation with OMVs also partially protected H. pylori against the bactericidal effects of the antibiotics clarithromycin and levofloxacin, but not against amoxicillin nor metronidazole. Addition of purified OMVs allowed H. pylori to grow in the presence of inhibitory concentrations of the antimicrobial peptide LL-37. In the presence of 50 µg OMVs ml−1, significantly enhanced H. pylori growth was observed at higher LL-37 concentrations compared with lower LL-37 concentrations, suggesting that OMV–LL-37 interactions might facilitate release of growth-promoting nutrients. Taken together, these data indicate that production of membrane vesicles could help H. pylori to survive exposure to antibiotics and host antimicrobial defences during infection.

27 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RBRuth Bowyer
Ruth Bowyer
TVThomas Varsavsky
Thomas Varsavsky
CSCarole H. Sudre
Carole H. Sudre
BMBenjamin A K Murray
Benjamin A K Murray
MFMaxim Freidin
Maxim Freidin
CMCristina Menni
Cristina Menni
Understanding the geographical distribution of COVID-19 through the general population is key to the provision of adequate healthcare services. Using self-reported data from 2,266,235 unique GB users of the COVID Symptom Tracker app , we find that COVID-19 prevalence and severity became rapidly distributed across the UK within a month of the WHO declaration of the pandemic, with significant evidence of “urban hot-spots”. We found a geo-social gradient associated with disease severity and prevalence suggesting resources should focus on urban areas and areas of higher deprivation. Our results demonstrate use of self-reported data to inform public health policy and resource allocation.

12 November 2025 in bioRxiv
Verified
Preprint
Open access
RMRamon Garcia Maset
Ramon Garcia Maset
ACAaron Crowther
Aaron Crowther
VCVictoria Chu
Victoria Chu
DGDavide Di Grande
Davide Di Grande
RJRizka O.A. Jariah
Rizka O.A. Jariah
JRJennifer L. Rohn
Jennifer L. Rohn
Urinary tract infections (UTI) remain a major global health burden, with high recurrence despite antibiotic treatment. The escalating prevalence of antimicrobial resistance further compromises therapeutic efficacy, contributing to an estimated 260,000 deaths annually. Conventional in vitro susceptibility assays often fail to predict clinical outcomes, underscoring the urgent need for physiologically relevant infection models. Here, we examined how microenvironmental complexity shapes uropathogenic Escherichia coli (UPEC) responses to antibiotics and bacteriophages using: human urine, a three-dimensional urothelial microtissue model (3D-UHU), and a novel mesofluidic system (P-FLO) that introduces physiologically relevant flow dynamics to the 3D-UHU. P-FLO was engineered from cost-effective 3D-printed components compatible with standard Transwell systems. Among the antibiotics tested, nitrofurantoin exhibited the greatest potency in minimum inhibitory concentration assays, but it failed to fully eradicate infection within the more physiological 3D-UHU model. A bacteriophage cocktail (LCPR1) showed markedly reduced activity in urine compared with nutrient-rich media, highlighting the influence of infection-site conditions. In contrast, in 3D-UHU, LCRP1 modulated host responses without reducing bacterial burden. Combination therapy (nitrofurantoin + LCPR1) eliminated planktonic bacteria under static conditions but offered no added benefit against adherent or intracellular populations relative to antibiotic monotherapy. Incorporating flow revealed additional layers of complexity, where shear stress induced bacterial elongation and attachment and altered drug performance, diminishing the efficacy of nitrofurantoin and combination therapy against planktonic populations despite increased drug exposure. Together, these findings demonstrate that the bladder microenvironment and its mechanical forces modulate host-pathogen interactions and profoundly influence UPEC infection dynamics and therapeutic outcomes, emphasizing the need for advanced, physiologically informed models to guide treatment strategies in the post-antibiotic era.

24 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
BMBenjamin O. Murray
Benjamin O. Murray
JGJinhui Gao
Jinhui Gao
KSKatherine Swarbrick
Katherine Swarbrick
AFAlex Freeman
Alex Freeman
JRJennifer L. Rohn
Jennifer L. Rohn
Bladder cancer cases and fatalities continue to rise worldwide with treatment outcomes not improving in the last four decades. Poor translation of potential new therapies from pre- clinical studies to the clinic could be one reason behind this. The patient-derived xenograft (PDX) mouse is the gold-standard for testing new bladder cancer therapies, but there are key physiological and molecular differences between mouse and human bladders. Thus, more human cell-based models may improve translation of treatments. Here, we introduce a bladder cancer microtissue model called 3D U rine-tolerant Hu man U rothelium-Tumour (3D-UHU-TU), which incorporates spheroids derived from human bladder cancer cell lines RT112 (low grade) and T24 (high grade) into the previously published 3D-UHU healthy urothelial model in a 100% urine environment. Both low- and high-grade 3D- UHU-TU models were characterised using immunofluorescence and immunohistochemistry staining with diagnostic markers (CK7, CK20 and GATA3), cadherin markers (E- and N-Cadherin), invasion and migration markers (MMP-2 and MMP-9) and a proliferation marker (Ki-67). Both models expressed the correct markers in the correct spatial areas. We also investigated the utility of both 3D-UHU-TU models as a platform to test treatments, using the conventional chemotherapeutic Mitomycin C as proof of principle. After 2 hours of treatment and 24 hours of recovery, cell lysis and nuclear damage were observed in both low- and high- grade cancer spheroids, with minimal damage to the surrounding healthy urothelium. At higher doses, cancer spheroids either disintegrated or were reduced in size, with the healthy urothelium still intact. Taken together, 3D-UHU-TU is a novel, in vitro model for testing both the safety and efficacy of new treatments. Furthermore, our work lays the foundation for testing treatments on patient-derived tumour spheroids in a personalised medicine approach.

2 June 2026 in British Journal of Cancer
Verified
Journal Article
Open access
BMBenjamin O. Murray
Benjamin O. Murray
JGJinhui Gao
Jinhui Gao
LPLaia Pasquina-Lemonche
Laia Pasquina-Lemonche
KSKatherine Swarbrick
Katherine Swarbrick
GSGuy Simpson
Guy Simpson
JRJennifer L. Rohn
Jennifer L. Rohn
Background: Despite therapy advances, better solutions for refractory bladder cancer remain an unmet need. Human cell-based models may aid in better treatment translation. We introduce 3D-UHU-TU, a bladder cancer microtissue model which incorporates spheroids derived from low- and high-grade human bladder cancer cell lines (RT112 and T24 respectively) into a healthy human urothelium. Methods: After model characterisation with histopathology and immunofluorescence microscopy, we trialled both the conventional chemotherapeutic Mitomycin C (MMC), and a novel herpes simplex oncolytic virus (oHSV-GFP), each assessed using confocal microscopy and cytotoxicity assays. Results: We observed correct expression of E- and N-Cadherin, CK7, CK20, GATA3 and Ki-67, alongside invasion and migration phenotypes. MMC treatment caused cell lysis and nuclear damage in cancer spheroids in both low- and high-grade models, with minimal damage to the surrounding healthy urothelium, and a significant increase in cleaved caspase 3 in low-grade models. oHSV-GFP co-localised in cancer spheroids and induced syncytia, spheroid disaggregation and cytotoxicity with minimal to no co-localisation or cytotoxicity in the healthy urothelium. Conclusion: 3D-UHU-TU model is useful for testing both treatment safety and efficacy on different grades of bladder cancer. Future use of primary tumour spheroids in place of cell lines may allow a personalised medicine approach.

4 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
RMRamon Garcia Maset
Ramon Garcia Maset
ACAaron Crowther
Aaron Crowther
VCVictoria Chu
Victoria Chu
DGDavide De Grandi
Davide De Grandi
RJRizka O. A. Jariah
Rizka O. A. Jariah
JRJennifer L. Rohn
Jennifer L. Rohn
Urinary tract infection (UTI) remains a major global health burden, with frequent recurrences and rising antimicrobial resistance compromising treatment efficacy. Conventional susceptibility assays often fail to predict clinical outcomes, highlighting the need for more physiologically relevant infection models. Here, we investigated how microenvironmental complexity influences uropathogenic Escherichia coli (UPEC) responses to antibiotics and bacteriophages using human urine, a three-dimensional human urothelial microtissue model (3D-UHU), and a novel mesofluidic platform (P-FLO) that applies physiologically relevant wall shear stress to 3D-UHU. Nitrofurantoin showed the greatest potency in conventional susceptibility assays but did not eradicate infection in the static 3D-UHU model. A bacteriophage cocktail (LCPR1) inhibited intracellular bacterial communities, preserved urothelial viability and induced inflammatory cytokine and chemokine secretion. Combined LCPR1 + nitrofurantoin treatment eliminated planktonic bacteria and reduced extracellular and intracellular bacterial communities under static conditions but did not further reduce urothelium-associated bacterial burden compared with nitrofurantoin alone. Under flow, shear stress promoted bacterial elongation, attachment and intracellular community formation, while reducing nitrofurantoin and combination therapy efficacy despite increased drug exposure. These findings demonstrate that the bladder microenvironment profoundly influences UPEC infection dynamics and therapeutic outcomes, underscoring the need for advanced models to guide treatment strategies in the antibiotic resistance era.